Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A new microparticle approach may offer hope for reversing multiple sclerosis

By Brian Buntz | June 16, 2023

False-colored MRI image of a brain hemisphere from a multiple sclerosis patient highlighting affected areas.

MRI image of a brain hemisphere from a multiple sclerosis patient, false-colored to highlight affected areas. Credit: Govind Bhagavatheeshwaran and Daniel Reich at NIH.

Johns Hopkins researchers have made strides in a study focusing on multiple sclerosis. By applying microparticles to activate regulatory T cells, they were able to reverse MS-like symptoms in mice.

There is no cure for multiple sclerosis (MS). But a recent study by Johns Hopkins Medicine shows encouraging progress towards: They have demonstrated the ability to reverse, and in many instances, entirely mitigate symptoms similar to multiple sclerosis in mice.

The study, published in the peer-reviewed journal Science Advances, found a reversal of the MS-like symptoms in 100% of mice receiving received tolerogenic microparticles (Tol-MPs). A total of 38% achieved a full recovery. The researchers measured improvement using a scoring system, where a lower score indicates less severe symptoms. Here, 100% refers to the portion of mice with a reduction in symptoms, lowering their score to 0.5 or less. The 38%, conversely, refers to the fraction of mice with a complete recovery, with their symptom severity score dropping to 0, representing no symptoms by the end of the study.

The bar chart below visualizes the median number of days for disease onset and the mean peak disease severity score for different treatments in the study. Each pair of bars represents a different treatment, with the left bar indicating the median time in days for disease onset and the right bar indicating the mean peak disease severity score. Lower values for both metrics indicate more effective treatments. The data for this chart are from the study published in Science Advances.

Bar chart showing the comparison of median days of disease onset and mean peak disease score for different treatments in a multiple sclerosis study. The treatments include control, rapamycin, tolerogenic microparticles, and a combination of rapamycin and microparticles.

Bar chart showing the comparison of median days of disease onset and mean peak disease score for different treatments in a multiple sclerosis study. The treatments include control, rapamycin, tolerogenic microparticles and a combination of rapamycin and microparticles.

“To be truly honest, I was surprised by how effective the therapy was in this mouse model,” said Dr. Giorgio Raimondi, one of the principal researchers involved in the study.

Raimondi noted that the study demonstrates a proof of principle for a strategy to address autoimmune diseases – type 1 diabetes is another potential application.

While results are promising, Raimondi stressed the need to “keep both feet on the ground. “There are many aspects that still need to be developed,” he noted.

Unveiling the promise of microparticles in multiple sclerosis

Polymeric microparticles show promise for inducing immune tolerance. While microparticles have existed for decades, the research was unique inits focus on using them as a framework to deliver multiple components simultaneously.

“These microscopic particles act as couriers, delivering therapeutic agents directly to the immune cells,” Raimondi explained. “They can interact with cell surface receptors or, following cellular internalization, deliver delicate biological cargo directly within cells.”

The biodegradability of these particles, made from a blend of poly(lactic co-glycolic acid) and poly(beta-amino ester), enables their dual functionality: The particles use both targeting ligands to direct therapy to the right cells and signaling ligands to deliver specific messages. They can also locally release encapsulated cargo, such as the immunosuppressant drug rapamycin as they biodegrade.

Targeting the immune system

In this research, ligands are involved in directing immunotherapy treatments to the appropriate immune cells and prompting the therapeutic response. Ligands are molecules that bind to specific sites on a target protein, triggering a change in its behavior. In the context of this research, two types of ligands are at work:

  1. Targeting ligands: These molecules help guide the therapy to the correct cells. They bind to specific receptors on the desired cell types to ensure that the therapy is delivered where it’s needed most. In this study, the researchers used an immunocytokine F5111 as a targeting ligand. F5111 IC is a modified version of interleukin-2 (IL-2), a protein that stimulates the growth and activity of T lymphocytes.
  2. Signaling ligands: These are molecules that, once inside the cell, send specific messages or instructions. These could include triggering the cell to behave in a certain way or to initiate specific processes. In this study, the researchers used MHC class II/peptide complexes as signaling ligands.

Using pathways that naturally induce immune tolerance, the researchers’ approach enables the delivery of therapeutic molecules to antigen-presenting cells (APCs). These APCs then stimulate an anti-inflammatory response.

Other notable recent examples of microparticle research include Rice University’s time-released drug delivery system and MIT’s ‘self-boosting’ vaccines.

Targeting T cells to combat multiple sclerosis

The Johns Hopkins study unveiled the potential use of microparticles to target and stimulate regulatory T cells (Tregs).

Tregs are a crucial type of immune cell that help keep the immune system in check, preventing it from mistakenly attacking the body’s own cells. In autoimmune diseases like MS, the number and function of these Tregs cells are often impaired or deficient, contributing to the immune system’s attack on its own tissues.

In the study, researchers engineered microparticles with F5111 IC and MHC class II/peptide complexes and laden with the immunosuppressant drug rapamycin, demonstrated the potential to both prevent and reverse paralysis in a mouse model of multiple sclerosis (experimental autoimmune encephalomyelitis or EAE).

The microparticles (MPs) in the research, also known as tolerogenic MPs (Tol-MPs), engage selectively with antigen-specific CD4+ T cells. Once administered intravenously, these MPs predominantly end up in the liver and spleen. Both local and systemic administrations of Tol-MPs effectively curbed the severity of EAE in mice.

The findings highlight the promise that Tol-MPs could offer. They have shown the capability to enable antigen-specific T cell engagement and selective Treg expansion, offering protection from autoimmune diseases like EAE.

Collaborators in the fight against multiple sclerosis

Dr. Jamie Spangler, an expert in engineering cytokines, developed a specialized interleukin-2 complex, targeting regulatory T cells to support their expansion and help maintain immune balance.

Another collaborator, Dr. Jordan Green, applied his expertise in material science and particles. Initially investigating  microparticles that activate the immune system against cancer, Green learned that such particles could also modulate other immune responses. Green and Spangler worked together to create microparticles carrying the tailored interleukin-2 (IL-2) complex that could target immune cells.

A collaborative approach to modulating the immune system

The team’s approach could treat MS and other autoimmune diseases with fewer side effects. “The particles attract cells and interact with cells and they can interact successfully only with cells that recognize that MHC,” says Raimondi. “Only the regulatory T cells will actually receive the signal from these interleukin-2 because it’s modified to communicate just with these regulatory cells and receive the signal to grow and expand as a population.”

Their system expands regulatory T cells without overly suppressing immunity. Green’s particles engage the T cells and deliver Spangler’s complex, promoting T cell growth to restore balance. “The whole point here is practically to work on the principle of the balance of the immune system in an autoimmune condition,” adds Raimondi.

This research marks a significant step toward personalized autoimmune therapies. Spangler, Green, and Raimondi’s work harnesses immunity in a precise and safe manner. It shows promise in transforming the treatment of autoimmune diseases and transplantation. “There are there is an activation and expansion of these autoreactive cells that need to be controlled,” Raimondi concludes, “Our approach is to use these particles to engage the population of regulatory cells, then it’s imbalanced, then it’s low, and bring it back up in a very antigen-specific way.”

The future of multiple sclerosis research: Next steps

Raimondi and his team have filed a patent application and plan to test the approach in other animal models of autoimmunity to explore its potential as a “platform technology.” As Raimondi points out, “We first demonstrated it can work and can work as a platform to indicate that we have these building blocks that are adaptable.” For example, they plan to swap the antigen target in the MS mouse model for one related to type 1 diabetes, indicating their versatility in application.

“I believe the future of autoimmune therapy is moving in the direction of more specific, more targeted approaches,” Raimondi said. “The microparticle platform offers this potential.”


Filed Under: Cell & gene therapy, Drug Delivery, Drug Discovery, Drug Discovery and Development, Uncategorized
Tagged With: autoimmune therapies, Johns Hopkins Medicine, microparticle technology, multiple sclerosis research, T cell stimulation, targeted drug delivery
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb
Recce targets A$15.8M to advance anti-infectives into Phase 3 trials
Vial of Steroid injection with a syringe on black table and stainless steel background.
The true cost of steroid-toxicity 
3D illustration of Palm painful - skeleton x-ray, medical concept.
Q&A: AnaptysBio’s CMO on rosnilimab’s ‘compelling’ phase 2b RA results
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE